GTC 9th Drug Design & Medicinal Chemistry Conference, 5-6 May 2015, Berlin, Germany HALLE/SAALE, Germany, 05 May 2015 – Probiodrug AG (“Probiodrug”, Euronext: PBD), a biopharmaceutical company […]
Patent grants strengthen IP position in Japan and follow issuance and grants in other important markets such as USA and Europe HALLE/SAALE, Germany, 23 April 2015 […]
Transformational year for Probiodrug IPO at Euronext Amsterdam completed Phase 2a study of novel treatment for Alzheimer’s disease ready for initiation in early 2015 First patient […]
HALLE/SAALE, Germany, 24 March 2015 – Probiodrug AG (Euronext Amsterdam: PBD), a biopharmaceutical company developing novel therapeutic solutions to treat Alzheimer’s disease, announces that Dr Hendrik Liebers, […]
Anti-pGlu-3 abeta monoclonal Antibody Ig isotype affects plaque clearance HALLE/SAALE, Germany, 20 March 2015 – Probiodrug AG (Euronext Amsterdam: PBD), a biopharmaceutical company developing novel therapeutic solutions […]
HALLE/SAALE, Germany, 18 March 2015 – Probiodrug AG (Euronext Amsterdam: PBD), a biopharmaceutical company developing novel therapeutic solutions to treat Alzheimer’s disease (AD), will publish its Annual Report […]
First patient enrolled at leading Alzheimer Center in Amsterdam HALLE/SAALE, Germany, 09 March 2015 – Probiodrug AG (Euronext Amsterdam: PBD), a biopharmaceutical company developing novel therapeutic solutions […]
Strong correlation between QCs and AD pathology in human brain biopsies underlines QC-inhibition as therapeutic approach HALLE/SAALE, Germany, 3 March 2015 – Probiodrug AG (“Probiodrug”, Euronext: PBD), a […]
HALLE/SAALE, Germany, 25 February 2015 – Probiodrug AG (“Probiodrug”, Euronext: PBD), a biopharmaceutical company developing novel therapeutic solutions to treat Alzheimer’s disease, announces that Probiodrug’s CEO and […]